Oklahoma ties state support for ibogaine trials to developer matching funds

The Oklahoma State Department of Health must contract with a drug developer to support multistate ibogaine trials. A developer must be a public, private, nonprofit, or for-profit organization involved in drug development and manufacturing, with an ibogaine development agreement with at least one other state and a plan for trials seeking federal approval. The duty applies only if funds are available. Before a contract, the developer must provide trial plans, participant-care protocols, proof of an agreement with another state or state-sponsored group, and financial disclosures. The contract must require the developer to match the state's investment and use the combined money for trials in Oklahoma, to the maximum extent possible using in-state clinicians, facilities, and participants. It must also address trial reports, treatment access after federal approval, and the state's proportional share of proceeds from trial-related intellectual property. The Department may agree to fair terms that provide substantially equivalent value to the state. The law takes effect November 1, 2026. The treatment-access plan must cover access after federal approval of ibogaine.

Drug developers must report trial progress and finances to the Health Department, which must report to state leaders. The developer reports on multistate ibogaine trials conducted under the law. The Department reports to the Governor, Senate President Pro Tempore, and House Speaker. The developer's financial report must include information verifying spending of state funds and required matching funds. The Department must report by December 1 each year until the trials conclude. The law takes effect November 1, 2026.

The law creates an Ibogaine Development Revolving Fund that the Health Department may spend on programs or research for at-risk people with conditions ibogaine may treat. Covered conditions include traumatic brain injury, opioid use disorder, other substance use disorders, and other neurological or mental health conditions treatable with ibogaine. The fund may receive the state's share of proceeds from trial-related intellectual property, legislative appropriations, donations, and public or private grants. Spending must follow required state payment procedures. The law takes effect November 1, 2026.

Oklahoma-licensed medical professionals cannot face professional discipline solely for recommending participation in ibogaine clinical trials. The protection covers medical professionals licensed in Oklahoma. The protection applies only when recommending trial participation is the sole basis for discipline. The law takes effect November 1, 2026.